Organic Compounds and Their Uses
First Claim
Patent Images
1. A compound of Formula I:
- and pharmaceutically acceptable salts thereof, whereinR1 is phenyl which may be unsubstituted or substituted;
R2 is het with at least one heteroring atom being N, and which may be unsubstituted or substituted;
L is lower alkyl, (CH2)1-2-A, A-(CH2)1-2, or CH2-A-CH2, and A is O, S, NH, or N-alkyl, wherein lower alkyl may be unsubstituted or substituted with lower alkyl, or one or more fluorines;
X is N or CH, and at least one X is N;
Y is a bond, CH2, C(O), or SO2;
R3 is aryl or het, which is substituted;
Z is H, lower alkyl, lower alkoxy, oxo, C(O)OR6, or —
CN;
in which lower alkyl and lower alkoxy may be unsubstituted or substituted with one or more halo, —
OH, —
CN, —
NH2, or oxo, and two Z connected to the same atom can form a cycloalkyl ring, and m is 0 to 3;
substitutions of phenyl, aryl or het of R1, R2, or R3 may be one or more of alkyl, cycloalkyl, alkoxy, cycloalkoxy, halo, —
CN, oxo, aryl, carbalkoxy, OCF3, CF3, OH, —
C(O)N(R6)2, C(O)R6, —
C(O)OR6, —
N(R6)2, —
NHC(O)R6, —
SO2(R6), —
SO2N(R6)2;
CH2OC(O)N(R6)2, —
CH2N(R6)2, —
NHC(O)OR6, NHC(O)N(R6)2, —
CH2NHC(O)R6, CH2NHC(O)N(R6)2, CH2NHSO2(R6), CH2NHC(O)OR6—
OC(O)R6, NHC(O)R6, O-aryl, het, or O-het, in which alkyl, het, cycloalkyl, cycloalkoxy, N(R6)2, aryl, carbalkoxy, and alkoxy can be unsubstituted or substituted with one or more halo, —
OCH3, —
OCF3, —
OH, —
NH2, alkyl, OR6, oxo, —
N(H)0-2—
R6, —
CN, —
C(O)N(R6)2, C(O)R6, C(O)OR6, —
N(R6)2, NHC(O)R6, —
SO2(R6), SO2N(R6)2, OSO2R6, —
CH2N(R6)2, —
CH2NHC(O)R6, —
OC(O)R6, aryl, NHC(O)(R6), O-aryl, het, O-het, or cycloalkyl;
R6 is H, alkyl, alkenyl, aryl, het, or two R6 on one atom may form cycloalkyl, aryl, or het; and
alkyl, alkenyl, aryl, het, cycloalkyl, or het may be unsubstituted or substituted by OH, oxo, alkoxy, NR6, Nalkyl, acyl, aryl or het group;
het is a 5-7 membered monocyclic heterocyclic ring which may be aromatic or non-aromatic, containing 1-4 heteroring atoms selected from N, O, and S;
or an 8-12 membered fused ring system that includes at least one 5-7 membered heterocyclic ring which may be aromatic or non-aromatic, containing 1, 2, or 3 heteroring atoms selected from N, O and S, which het is unsubstituted or substituted;
aryl is an aromatic radical having 6 to 14 ring carbon atoms, and no ring heteroatoms, in which said aryl group may be monocyclic or fused bicyclic or tricyclic, which may be unsubstituted or substituted by one or more substituents; and
n is 0, 1, 2, or 3.
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure relates to compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders; specifically relating to compounds of formula I:
-
Citations
10 Claims
-
1. A compound of Formula I:
-
and pharmaceutically acceptable salts thereof, wherein R1 is phenyl which may be unsubstituted or substituted; R2 is het with at least one heteroring atom being N, and which may be unsubstituted or substituted; L is lower alkyl, (CH2)1-2-A, A-(CH2)1-2, or CH2-A-CH2, and A is O, S, NH, or N-alkyl, wherein lower alkyl may be unsubstituted or substituted with lower alkyl, or one or more fluorines; X is N or CH, and at least one X is N; Y is a bond, CH2, C(O), or SO2; R3 is aryl or het, which is substituted; Z is H, lower alkyl, lower alkoxy, oxo, C(O)OR6, or —
CN;
in which lower alkyl and lower alkoxy may be unsubstituted or substituted with one or more halo, —
OH, —
CN, —
NH2, or oxo, and two Z connected to the same atom can form a cycloalkyl ring, and m is 0 to 3;substitutions of phenyl, aryl or het of R1, R2, or R3 may be one or more of alkyl, cycloalkyl, alkoxy, cycloalkoxy, halo, —
CN, oxo, aryl, carbalkoxy, OCF3, CF3, OH, —
C(O)N(R6)2, C(O)R6, —
C(O)OR6, —
N(R6)2, —
NHC(O)R6, —
SO2(R6), —
SO2N(R6)2;
CH2OC(O)N(R6)2, —
CH2N(R6)2, —
NHC(O)OR6, NHC(O)N(R6)2, —
CH2NHC(O)R6, CH2NHC(O)N(R6)2, CH2NHSO2(R6), CH2NHC(O)OR6—
OC(O)R6, NHC(O)R6, O-aryl, het, or O-het, in which alkyl, het, cycloalkyl, cycloalkoxy, N(R6)2, aryl, carbalkoxy, and alkoxy can be unsubstituted or substituted with one or more halo, —
OCH3, —
OCF3, —
OH, —
NH2, alkyl, OR6, oxo, —
N(H)0-2—
R6, —
CN, —
C(O)N(R6)2, C(O)R6, C(O)OR6, —
N(R6)2, NHC(O)R6, —
SO2(R6), SO2N(R6)2, OSO2R6, —
CH2N(R6)2, —
CH2NHC(O)R6, —
OC(O)R6, aryl, NHC(O)(R6), O-aryl, het, O-het, or cycloalkyl;R6 is H, alkyl, alkenyl, aryl, het, or two R6 on one atom may form cycloalkyl, aryl, or het; and
alkyl, alkenyl, aryl, het, cycloalkyl, or het may be unsubstituted or substituted by OH, oxo, alkoxy, NR6, Nalkyl, acyl, aryl or het group;het is a 5-7 membered monocyclic heterocyclic ring which may be aromatic or non-aromatic, containing 1-4 heteroring atoms selected from N, O, and S;
or an 8-12 membered fused ring system that includes at least one 5-7 membered heterocyclic ring which may be aromatic or non-aromatic, containing 1, 2, or 3 heteroring atoms selected from N, O and S, which het is unsubstituted or substituted;aryl is an aromatic radical having 6 to 14 ring carbon atoms, and no ring heteroatoms, in which said aryl group may be monocyclic or fused bicyclic or tricyclic, which may be unsubstituted or substituted by one or more substituents; and n is 0, 1, 2, or 3. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
(where N is connected to L),where U is C(H)0-1 or N, and not more than two U are N; R4 is independently H, —
N(R6)2, —
OH, halo, —
CN, —
C(O)OR6, —
C(O)N(R6)2, lower alkyl, or lower alkoxy, in which lower alkyl and lower alkoxy may be unsubstituted or substituted with one or more halo, —
OH, —
CN, —
NH2, —
NO2, —
C(O)NH2, —
C(O)NH(C1-C6-alkyl), —
C(O)N(C1-C6-alkyl)2, —
C(O)(C1-C6-alkyl), —
NHC(O)(C1-C6-alkyl), NH(C1-C6-alkyl), —
N(C1-C6-alkyl)2, —
SO2(C1-C6-alkyl), —
SO2NH2, —
SO2NH(C1-C6 alkyl);R5 is H, aryl, het, lower alkyl, lower alkoxy, or cycloalkyl, which can be unsubstituted or substituted with one or more halo, cycloalkyl, aryl, het, and wherein at least one R5 is not H; and
L is lower alkyl.
-
-
3. The compound according to claim 1 wherein R2 is selected from:
-
wherein W is O, NR7 or SO2 and R7 is H, a bond, lower alkyl or lower acyl.
-
-
4. The compound according to claim 1 wherein R2 is:
-
and R3 is het.
-
-
5. The compound according to claim 2 wherein:
-
R3 is aryl or het; and
when R3 is het, at least one heteroring atom is N;U is C(H)0-1; R4 is H, CH3, halo or —
CN;L is CH2; X is N; Y is a bond; and Z is H or CH3.
-
-
6. The compound according to claim 5 wherein:
-
R2 is R4 is H, and U is C(H)0-1, R3 is phenyl, pyridine, pyrazine, pyridazine or pyrimidine Z is H or CH3 and n is 1.
-
-
7. The compound according to claim 5 wherein:
-
R2 is selected from;
where N is connected to L;and at least one R5 is CH3.
-
-
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1.
-
9. A method of treating a mammal suffering from a pathology relating to the Hedgehog pathway which comprises administering to said mammal in need of treatment a therapeutically effective amount of a compound according to claim 1.
-
10. A compound selected from:
6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-nicotinonitrile;
1-Benzyl-4-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-phthalazine;
1-Benzyl-4-[4-(5-trifluoromethyl-pyridin-2-yl)-[1,4]diazepan-1-yl]-phthalazine;
6-[4-(4-Pyridin-4-ylmethyl-phthalazin-1-yl)-piperazin-1-yl]-nicotinonitrile;
4-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-benzoic acid ethyl ester;
1-(4-Phenyl-piperazin-1-yl)-4-pyridin-4-ylmethyl-phthalazine;
1-Benzyl-4-[4-(4-tert-butyl-phenyl)-piperazin-1-yl]-phthalazine;
1-[4-(4-tert-Butyl-phenyl)-piperazin-1-yl]-4-pyridin-4-ylmethyl-phthalazine;
1-[4-(4-tert-Butyl-phenyl)-piperazin-1-yl]-4-(3,5-dichloro-benzyl)-phthalazine;
4-[4-(4-tert-Butylphenyl)-piperazin-1-yl]-6-methyl-1-pyridin-4-ylmethyl-phthalazine;
1-(2-Methyl-pyridin-4-ylmethyl)-4-(4-phenyl-piperazin-1-yl)-phthalazine;
1-Benzyl-4-(4-phenylpiperidin-1-yl)-phthalazine;
1-(4-Phenyl-piperidin-1-yl)-4-pyridin-4-ylmethyl-phthalazine;
1-(2-Methyl-pyridin-4-ylmethyl)-4-(4-phenyl-piperidin-1-yl)-phthalazine;
1-Pyridin-4-ylmethyl-4-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-phthalazine;
4-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-benzoic acid;
1-Benzyl-4-[4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-[1,4]diazepan-1-yl]-phthalazine;
1-Benzyl-4-(4-quinolin-2-yl-piperazin-1-yl)-phthalazine;
6-[4-(4-Benzyl-phthalazin-1-yl)-[1,4]diazepan-1-yl]-nicotinonitrile;
4-(4-Pyridin-4-ylmethyl-phthalazin-1-yl)-3,4,5,6-tetrahydro-2H-[1,2′
]bipyrazinyl;
4-(4-Benzyl-phthalazin-1-yl)-3,4,5,6-tetrahydro-2H-[1,2′
]bipyrazinyl;
1-(2-Methyl-pyridin-4-ylmethyl)-4-(4-pyridin-2-yl-piperazin-1-yl)-phthalazine;
1-Pyridin-4-ylmethyl-4-(4-pyridin-2-yl-piperazin-1-yl)-phthalazine;
1-Benzyl-4-(4-pyridin-2-yl-piperazin-1-yl)-phthalazine;
1-Benzyl-4-(4-pyrimidin-2-yl-piperazin-1-yl)-phthalazine;
1-Pyridin-4-ylmethyl-4-(4-pyridin-4-yl-piperazin-1-yl)-phthalazine;
1-Benzyl-4-(3-methyl-4-p-tolyl-piperazin-1-yl)-phthalazine;
1-(3-Methyl-4-p-tolylpiperazin-1-yl)-4-pyridin-4-ylmethyl-phthalazine;
1-(2-Methyl-pyridin-4-ylmethyl)-4-(3-methyl-4-p-tolyl-piperazin-1-yl)-Phthalazine;
1-Benzyl-4-[4-(3,4-dichloro-phenyl)-piperazin-1-yl]-phthalazine;
1-Benzyl-4-(4-naphthalen-2-yl-piperazin-1-yl)-phthalazine;
1-(4-Naphthalen-2-yl-piperazin-1-yl)-4-pyridin-4-ylmethyl-phthalazine;
1-(2-Methylpyridin-4-ylmethyl)-4-(4-naphthalen-2-yl-piperazin-1-yl)-phthalazine;
1-Benzyl-4-(4-naphthalen-1-yl-piperazin-1-yl)-phthalazine;
1-(2-Methyl-pyridin-4-ylmethyl)-4-(4-naphthalen-1-yl-piperazin-1-yl)-phthalazine;
1-(4-Naphthalen-1-yl-piperazin-1-yl)-4-pyridin-4-ylmethyl-phthalazine;
1-Benzyl-4-(4-pyridin-4-yl-piperazin-1-yl)-phthalazine;
1-Benzyl-4-(4-o-tolyl-piperazin-1-yl)-phthalazine;
2-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyrimidine-5-carbonitrile;
1-Benzyl-4-(4-pyrimidin-2-yl-[1,4]diazepan-1-yl)-phthalazine;
1-Benzyl-4-[4-(4-methyl-pyrimidin-2-yl)-[1,4]diazepan-1-yl]-phthalazine;
1-Benzyl-4-[4-(5-propyl-pyrimidin-2-yl)-piperazin-1-yl]-phthalazine;
1-Benzyl-4-[4-(5-ethyl-pyrimidin-2-yl)-piperazin-1-yl]-phthalazine;
1-Benzyl-4-[4-(5-propyl-pyrimidin-2-yl)-[1,4]diazepan-1-yl]-phthalazine;
1-Benzyl-4-[4-(5-ethylpyrimidin-2-yl)-[1,4]diazepan-1-yl]-phthalazine;
2-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-6-methoxy-3H-pyrimidin-4-one;
1-Benzyl-4-[4-(4-methyl-pyrimidin-2-yl)-piperazin-1-yl]-phthalazine;
1-Benzyl-4-[4-(4,6-dimethyl-pyrimidin-2-yl)-piperazin-1-yl]-phthalazine;
1-Benzyl-4-[4-(5-chloro-3-fluoro-pyridin-2-yl)-piperazin-1-yl]-phthalazine;
1-Benzyl-4-[4-(4-trifluoromethyl-pyrimidin-2-yl)-piperazin-1-yl]-phthalazine;
1-Benzyl-4-[4-(2,5-difluoro-pyridin-3-yl)-piperazin-1-yl]-phthalazine;
1-Benzyl-4-[4-(3,5-difluoro-pyridin-2-yl)-piperazin-1-yl]-phthalazine;
6-[4-(4-Benzylphthalazin-1-yl)-piperazin-1-yl]-nicotinamide;
6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-nicotinic acid ethyl ester;
2-{6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyridin-3-yl}-propan-2-ol;
6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-nicotinic acid;
6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-N-(2-hydroxy-ethyl)-N-methylnicotinamide;
6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-N-ethyl-N-(2-hydroxyethyl)-nicotinamide;
6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-N-(2-hydroxyethyl)-nicotinamide;
6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-N-(2-methoxyethyl)-nicotinamide;
6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-N-(2-methoxy-ethyl)-N-methyl-nicotinamide;
6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-N-(2-dimethylamino-ethyl)-nicotinamide;
{6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyridin-3-yl}-(4-methyl-piperazin-1-yl)-methanone;
{6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyridin-3-yl}-piperazin-1-yl-methanone;
{6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyridin-3-yl}-morpholin-4-yl-methanone;
N-Benzyl-6-[4-(4-benzylphthalazin-1-yl)-piperazin-1-yl]-nicotinamide;
6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-N-cyclohexylmethyl-nicotinamide;
6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-N-propyl-nicotinamide;
{6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyridin-3-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone;
{6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyridin-3-yl}-thiazolidin-3-yl-methanone;
{6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyridin-3-yl}-(1-oxo-1lambda*4*-thiazolidin-3-yl)-methanone;
({6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyridine-3-carbonyl}-amino)-acetic acid methyl ester;
1-Benzyl-4-[4-(4-trifluoromethyl-phenyl)-piperazin-1-yl]-phthalazine;
6-{4-[4-(3-Trifluoromethyl-benzyl)-phthalazin-1-yl]-piperazin-1-yl}-nicotinonitrile;
6-{4-[4-(4-Cyano-benzyl)-phthalazin-1-yl]-piperazin-1-yl}-nicotinonitrile;
6-{-4-[4-(3,4-Dimethoxy-benzyl)-phthalazin-1-yl]-piperazin-1-yl}-nicotino-nitrile;
6-{-4-[4-(4-Chlorobenzyl)-phthalazin-1-yl]-piperazin-1-yl}-nicotinonitrile;
6-{4-[4-(3-Chloro-benzyl)-phthalazin-1-yl]-piperazin-1-yl}-nicotinonitrile;
6-[4-(4-Phenethyl-phthalazin-1-yl)-piperazin-1-yl]-nicotinonitrile;
6-[4-(4-Naphthalen-2-ylmethyl-phthalazin-1-yl)-piperazin-1-yl]-nicotino-nitrile;
6-{-4-[4-(4-Trifluoromethyl-benzyl)-phthalazin-1-yl]-piperazin-1-yl}-nicotinonitrile;
6-{-4-[4-(4-Methoxy-benzyl)-phthalazin-1-yl]-piperazin-1-yl}-nicotinonitrile;
6-{4-[4-(3-Cyano-benzyl)-phthalazin-1-yl]-piperazin-1-yl}-nicotinonitrile;
6-{4-[4-(4-Bromo-benzyl)-phthalazin-1-yl]-piperazin-1-yl}-nicotinonitrile;
6-{4-[4-(3-Bromo-benzyl)-phthalazin-1-yl]-piperazin-1-yl}-nicotinonitrile;
6-{4-[4-(1-Phenyl-ethyl)-phthalazin-1-yl]-piperazin-1-yl}-nicotinonitrile;
6-{4-[4-(4-Methyl-benzyl)-phthalazin-1-yl]-piperazin-1-yl}-nicotinonitrile;
N-{6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyridin-3-ylmethyl}-acetamide;
C-{6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyridin-3-yl}-methyl-amine;
4-[4-(4-Pyridin-4-ylmethyl-phthalazin-1-yl)-piperazin-1-yl]-benzylamine;
4-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-benzylamine;
4-[5-({6-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-pyridin-3-ylmethyl}-carbamoyl)-pentyl]-8-ethyl-3,8,9,10-tetrahydro-2H-1,6,11-trioxa-8,13-diaza-4-azonia-pentacene;
N-{-4-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-benzyl}-acetamide;
N-{-4-[4-(4-Pyridin-4-ylmethyl-phthalazin-1-yl)-piperazin-1-yl]-benzyl}-acetamide;
{4-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-benzyl}-carbamic acid benzyl ester;
{4-[4-(4-Pyridin-4-ylmethyl-phthalazin-1-yl)-piperazin-1-yl]-benzyl}-carbamic acid benzyl ester;
N-{4-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-benzyl}-propionamide;
N-{-4-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-benzyl}-2-methoxyacetamide;
N-{4-[4-(4-Benzyl-phthalazin-1-yl)-piperazin-1-yl]-benzyl}-3-methylbutyramide;
6-[4-(1-Benzyl-isoquinolin-4-yl)-piperazin-1-yl]-nicotinonitrile;
6-{4-[1-(3-Cyano-benzyl)-isoquinolin-4-yl]-piperazin-1-yl}-nicotinonitrile;
6-{4-[1-(3-Chlorobenzyl)-isoquinolin-4-yl]-piperazin-1-yl}-nicotinonitrile;
6-{4-[1-(3-Trifluormethyl-benzyl)-isoquinolin-4-yl]-piperazin-1-yl}-nicotinonitrile;
6-[4-(4-Benzyl-isoquinolin-1-yl)-piperazin-1-yl]-nicotinonitrile;
4-{4-[6-(4-Fluoro-benzyl)-4-methyl-pyridazin-3-yl]-piperazin-1-yl}-benzo-nitrile;
4-{4-[6-(4-Fluoro-benzyl)-5-methyl-pyridazin-3-yl]-piperazin-1-yl}-benzo-nitrile;
4-{4-[6-(4-Benzyl)-4-methyl-pyridazin-3-yl]-piperazin-1-yl}-nicotinonitrile;
4-{-4-[6-(4-Benzyl)-5-methyl-pyridazin-3-yl]-piperazin-1-yl}-nicotinonitrile;
6-Benzyl-4-methyl-3-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyridazine;
6-Benzyl-5-methyl-3-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyridazine;
6-(4-Fluoro-benzyl)-4-methyl-3-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyridazine;
6-(4-Fluoro-benzyl)-5-methyl-3-[4-(5-trifluoromethylpyridin-2-yl)-piperazin-1-yl]-pyridazine;
4-{-4-[6-(4-chloro-benzyl)-4-methyl-pyridazin-3-yl]-piperazin-1-yl}-nicotinonitrile;
4-{4-[6-(4-chloro-benzyl)-5-methyl-pyridazin-3-yl]-piperazin-1-yl}-nicotinonitrile;
4-{4-[6-(4-Fluoro-benzyl)-4,5-dimethyl-pyridazin-3-yl]-piperazin-1-yl}-nicotinonitrile;
4-{4-[4-(4-fluoro-benzyl)-5,6,7,8-tetrahydro-phthalzin-1-yl]-piperazin-1-yl}-nicotinonitrile;
6-{4-[4-(4-Fluoro-benzyl)-6,7-dihydro-5H-cyclopenta[d]pyridazin-1-yl]-piperazin-1-yl}-nicotinonitrile;
3-{4-[1-(4-Fluorobenzyl)-1H-indol-3-yl]-piperidine-1-carbonyl}-benzo-nitrile;
4-[1-(4-Fluoro-benzyl)-1H-indol-3-yl)-5′
-trifluoromethyl-3,4,5,6-tetra-hydro-2H-[1,2]-bipyridinyl;
4-[3-(5′
-Trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2′
]bipyridinyl-4-yl)-indol-1-ylmethyl]-benzonitrile;
4-[1-Benzyl-1H-indol-3-yl)-5′
-trifluoromethyl-3,4,5,6-tetra-hydro-2H-[1,2]-bipyridinyl;
4-[1-(4-Fluoro-benzyl)-1H-indol-3-yl]-3,4,5,6-tetrahydro-2H-[1,2′
]bipyridinyl-5′
-carbonitrile;
4-[1-(4-Bromo-benzyl)-1H-indol-3-yl)-5′
-trifluoromethyl-3,4,5,6-tetra-hydro-2H-[1,2]-bipyridinyl;
4-(1-Benzyl-1H-indol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2′
]bipyridinyl-5′
-carbonitrile;
{4-[1-(4-Fluoro-benzyl)-1H-indol-3-yl]-piperidin-1-yl}-(3-fluoro-phenyl)-methanone;
4-{4-[1-(4-Fluoro-benzyl)-1H-indol-3-yl]-piperidine-1-carbonyl}-benzonitrile;
3-{4-[1-(4-Fluoro-benzyl)-1H-indol-3-yl]-piperidine-1-carbonyl}-benzonitrile;
{4-[1-(4-Fluoro-benzyl)-1H-indol-3-yl]-piperidin-1-yl}-(4-trifluoromethyl-phenyl)-methanone;
or {4-[1-Benzyl-1H-indol-3-yl]-piperidin-1-yl}-(4-trifluoromethyl-phenyl)-methanone.
Specification